Written by the Nuvirox Research Team
Key points
- Andrew Huberman, a Stanford neuroscientist and popular podcaster, advises against using melatonin as a nightly sleep aid for most people.
- His main concerns: supplement doses are far higher than the body’s natural output, melatonin is a hormone that may affect other hormone systems, and it helps you fall asleep but not stay asleep.
- Most of his points are well-grounded; a couple (like “it won’t keep you asleep”) are more contested than his framing suggests.
Short answer: Huberman’s caution about nightly high-dose melatonin is largely well-founded, even if a few of his specific claims are debated. He’s become one of the most influential voices telling people not to take melatonin every night, and his reasoning tracks much of the mainstream research: most supplements deliver supraphysiological doses, melatonin is a hormone with effects beyond sleep, and its benefit for staying asleep is weak. Where reasonable experts push back is on how absolute some of those statements are. This piece lays out his position and checks it against the evidence — without telling you what to do.
What does Huberman actually say about melatonin?
His position, stated across his podcast and Q&A sessions, is consistent: he doesn’t recommend melatonin as a routine nightly sleep aid for most people, and he reserves it mainly for specific situations like jet lag, at low doses. His core arguments are that typical supplement doses (often 3-10 mg) are many times the body’s natural nightly output of roughly 0.1-0.3 mg; that melatonin is a hormone that can influence other hormone systems, including reproductive hormones; that it may help you fall asleep but not stay asleep; and that supplement label accuracy is poor. He emphasizes behavioral tools — especially morning light — as higher-priority levers than any supplement.
One of Huberman’s central points: typical melatonin supplements deliver many times the body’s own nightly output, which he argues is unnecessary and potentially counterproductive.
How well do his arguments hold up?
The dose argument is solid. The body’s nightly melatonin output is indeed small, and many supplements deliver 10-30 times more. Controlled research on circadian timing found that 0.5 mg produced nearly the same phase shift as 3.0 mg — supporting the idea that low doses are often sufficient and high doses aren’t clearly better. On this, Huberman is aligned with the evidence.
The hormone and label-accuracy concerns are legitimate. Melatonin is a hormone, and his caution about chronic high doses and potential effects on other hormone systems is a reasonable conservative stance, particularly for younger people. His point about poor label accuracy is well-documented: testing has found melatonin content ranging wildly from labels, as we cover in synthetic melatonin. These are fair, evidence-grounded concerns.
The “won’t keep you asleep” claim is the most contested. Huberman often cites the modest average effect of melatonin — for instance, meta-analytic estimates of only a few minutes’ increase in total sleep — to argue it doesn’t help sleep maintenance. That’s defensible, but it’s not the whole story. Some meta-analyses do report improvements in total sleep time and sleep quality, and effects vary by population (melatonin looks more useful in older adults). So “melatonin won’t keep you asleep” is better stated as “melatonin’s sleep-maintenance benefit is small and inconsistent.”
What human studies actually show
The evidence broadly supports Huberman’s emphasis on timing over dose. Phase-response research shows melatonin’s most reliable effect is shifting the clock, with low doses sufficient. It partly complicates his sleep-maintenance dismissal: meta-analyses are mixed, with some finding small but real improvements in sleep latency, total sleep, and quality, and stronger effects in specific groups. And it supports his caution on dosing and labels: supraphysiological doses are common and accuracy is poor. The net is that Huberman is more right than wrong, but his strongest single claim — that melatonin essentially doesn’t help you stay asleep — is the one to hold loosely.
What this means for you
The reasonable, evidence-consistent takeaways from the Huberman discussion are: prioritize behavioral sleep tools (consistent schedule, morning light, dim evenings) first; if you use melatonin, a lower dose is often as good as a high one; reserve melatonin especially for timing problems like jet lag rather than as an indefinite nightly crutch; and choose accurately labeled products. None of that requires agreeing with every word he’s said — it’s just where his better arguments and the research converge.
The morning-light point most people miss
Buried in the melatonin debate is the tool Huberman actually emphasizes more than any supplement: morning light. Getting bright light into your eyes early in the day is one of the most powerful, best-supported ways to anchor your circadian clock — it sets the timing reference your whole system runs on, including when your own melatonin rises that evening. In that sense, sorting out your light exposure does upstream what people hope melatonin will do downstream.
This reframes the whole melatonin question. If your clock is well-anchored by consistent morning light and dim evenings, you may not need a melatonin supplement at all; if it’s not, melatonin is a weaker, downstream patch. That ordering — behavior first, supplement second — is where Huberman and the circadian-research literature genuinely agree, and it’s the most actionable takeaway from the entire discussion, regardless of how you weigh his more contested claims about sleep maintenance.
Frequently asked questions
Does Andrew Huberman recommend melatonin?
Not as a nightly sleep aid for most people. He reserves it mainly for situations like jet lag at low doses, and emphasizes behavioral tools — especially morning light — over supplements.
Why is Huberman against melatonin?
His main reasons are that supplement doses far exceed the body’s natural output, melatonin is a hormone that may affect other hormone systems, label accuracy is poor, and he argues it doesn’t help you stay asleep. Most of these are evidence-grounded.
Is Huberman right that melatonin won’t keep you asleep?
Partly. The sleep-maintenance benefit is small and inconsistent, but some meta-analyses do find modest improvements, and effects vary by group. “Small and inconsistent” is more accurate than “none.”
What dose does Huberman suggest if you do use it?
He points toward low doses for specific uses like jet lag, consistent with research showing low doses produce nearly the same circadian effect as higher ones. Always reasonable to discuss with a clinician.
From Nuvirox
Why we formulated Sleep+ Restore
Consistent with the low-and-occasional view, Sleep+ Restore is meant to be used thoughtfully — and it pairs melatonin with botanicals rather than relying on a melatonin megadose. As with any supplement, behavioral basics come first. Sleep+ Restore combines melatonin with vitamin B6 and a botanical blend (L-theanine, lemon balm, passionflower, chamomile, ashwagandha, GABA)’so the formula doesn’t lean on melatonin to do all the work.
Every order is covered by a 60-day money-back guarantee’long enough to actually evaluate it the way the research says you should.
Learn more about Sleep+ Restore →The bottom line
Andrew Huberman’s skepticism about nightly melatonin is mostly well-founded: supplement doses dwarf the body’s natural output, melatonin is a hormone worth respecting, and label accuracy is genuinely poor. His weakest claim is the flat “it won’t keep you asleep,” which the mixed meta-analytic evidence softens. The sensible synthesis: behavioral tools first, low doses if you use it, and melatonin best reserved for timing problems.
References
- Burgess HJ, Revell VL, Molina TA, Eastman CI. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. J Clin Endocrinol Metab. 2010;95(7):3325-3331. PMC3696986.
- Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.
- Cohen PA, Avula B, et al. Quantity of melatonin and CBD in melatonin gummies sold in the US. JAMA. 2023;329(16):1401-1402. doi:10.1001/jama.2023.2296.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.